Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2095 results about "Viral vector" patented technology

Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells. This process can be performed inside a living organism (in vivo) or in cell culture (in vitro). Viruses have evolved specialized molecular mechanisms to efficiently transport their genomes inside the cells they infect. Delivery of genes, or other genetic material, by a vector is termed transduction and the infected cells are described as transduced. Molecular biologists first harnessed this machinery in the 1970s. Paul Berg used a modified SV40 virus containing DNA from the bacteriophage λ to infect monkey kidney cells maintained in culture.

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

ActiveUS12274733B2Senses disorderNervous disorderTissue repairVaccine virus
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Methods for making genetic regulatory elements

The present invention provides methods, computer systems and computer-implemented products for making synthetic regulatory elements, and provides polynucleotide's, transgenic cells, and transgenic organisms (including viruses and viral vectors) produced by these methods. The invention thereby provides regulatory sequences to meet various gene expression objectives, including the ability to stack a plurality of heterologous genes for expression in a single cell, while avoiding gene silencing or reduced expression levels.
Owner:MONSANTO TECHNOLOGY LLC

Recombinant live virus vector rabies vaccine without neurotoxicity

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.
Owner:HEFEI BAIYU BIOTECHNOLOGY CO LTD +1

Viral delivery of neoantigens

Disclosed herein are chimpanzee adenoviral vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
Owner:SEATTLE PROJECT CORP

Anti-CD90 antibodies, binding fragments, and uses thereof

Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therapeutic purpose. Anti-CD90 antibodies and binding fragments thereof can also be used in engineered formats to create multi-domain binding molecules, antibody conjugates, recombinant receptors, or within a recombinant protein to pseudotype viral vectors.
Owner:FRED HUTCHINSON CANCER CENT

Gene therapy for diseases with CNS manifestation

The present disclosure relates generally to viral vectors comprising an engineered transgene capable of crossing the blood brain barrier and their use in treating diseases with central nervous system performance, such as, but not limited to, Hunter Syndrome, Gaucher Disease, and Swefil Syndrome.
Owner:TAKEDA PHARMA CO LTD

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Virus particle identification method based on negative staining electron microscope image

The invention provides a virus particle identification method based on a negative staining electron microscope image. The deep learning and image segmentation technology is adopted to automatically identify virus particles and classify hollow and solid virus particles in the negative staining electron microscope image, so that the real heart rate and the virus particle concentration of the virus are obtained, and the requirement on the purity of a sample is low. Therefore, the production quality control process of the virus vector can be improved, and the development and optimization of gene therapy can be accelerated.
Owner:LOTUSLAKE BIOMEDICAL TECH CO LTD

A self-activating small molecule induction system, cells, and applications and methods in inducing gene expression

The present invention provides a self-activating small molecule induction system, cells, and applications and methods in inducing gene expression, belonging to the technical field of genetic engineering. The self-activating small molecule induction system optimizes the component composition based on the green light response system, improves the induction efficiency of the target gene through a cascade reaction, and can reduce the background leakage level, playing an important role in the induction of the target gene and having good application prospects in the field of protein expression and the production and preparation of viral vectors.
Owner:GENMEDICN BIOPHARMA INC

Machine learning guided design of viral vector libraries

Various methods and systems are provided for designing viral vector libraries using machine learning models. In some embodiments, by training a machine learning model to predict a packaging fitness of a viral vector sequence, a viral vector library may be designed, wherein, for a desired library diversity, an increased packaging fitness may be achieved. In one example, a machine learning model may be trained to predict packaging fitness of a viral vector sequence by encoding the viral vector sequence as a feature set, mapping the feature set to a predicted packaging fitness of the viral vector sequence using a machine learning model, determining a loss based on a difference between a ground truth packaging fitness and the predicted packaging fitness of the viral vector sequence, and updating parameters of the machine learning model based on the loss.
Owner:CZ BIOHUB SF LLC +1

Targeting carrier and preparation method and application thereof

The invention provides a targeting vector and a method for targeting a host cell, the vector comprises a first molecule combined with an endocytosis receptor of a target cell and a second molecule for promoting release of a substance carried by the targeting vector into cytoplasm, when the targeting vector is a virus vector, the first molecule is not a part of a virus envelope protein, and the second molecule is not a part of a virus envelope protein. The second molecules promote endosome escape or lysosome escape of the targeting carrier. According to the present invention, the first molecule is designed according to the endocytosis receptor of the to-be-targeted cell so as to target different types of cells, and after the vector is subjected to reasonable mutation, the infection of the cells not requiring the targeting can be avoided, and the accuracy of the vector can be improved.
Owner:SHENZHEN GENOCURY BIOTECH CO LTD

Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing

Provided herein are modified Staphylococcus aureus Cas9 nucleases and methods of using modified Staphylococcus aureus Cas9 nucleases. Also provided herein are chimeric nucleases comprising an I-Tevl nuclease domain, and a Staphylococcus aureus Cas9 and methods of using the chimeric nuclease. Also provided herein are methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.
Owner:SPECIFIC BIOLOGICS INC

Viral vector and producer cell

PCT designated stage expiredWO2025003526A1SsRNA viruses negative-senseAntibody mimetics/scaffoldsType specificViral envelope
There is provided a viral vector having a lipid bilayer envelope comprising an antibody binding domain displayed on the exterior of the envelope that is cell-type specific; a viral envelope protein displayed on the exterior of the envelope that is able to facilitate infection of the same cell type; and a nucleic acid molecule comprising a promoter expressible in the same cell type. Further provided are methods of making the viral vector and methods of using the viral vector to modify cells and treat diseases / conditions.
Owner:ESOBIOTEC

Methods and compositions relating to the treatment of tumors

Described herein are methods and compositions relating to the treatment of a tumor (e.g., schwannoma) by increasing expression of Apoptosis-associated Speck-like protein containing a CARD (ASC) and / or gasdermin D. In some embodiment, the increased expression is provided by means of a vector or construct comprising a nucleic acid encoding Apoptosis-associated Speck-like protein containing a CARD (ASC) and / or gasdermin D operably linked to a Schwann-lineage cell-specific promoter. In some embodiments, the vector is a viral vector.
Owner:THE GENERAL HOSPITAL CORP

Novel therapeutic drug for treating PROM1-associated retinal disease

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.
Owner:SHANGHAI INNOSTELLAR BIOTHERAPEUTICS CO LTD

CD19-specific antibody constructs and compositions thereof

Disclosed herein are antibodies or antigen-binding fragments thereof that specifically bind to human CD19. Chimeric antigen receptors and chimeric antigen receptor transgenes comprising an antigen binding domain that specifically binds to human CD19 are also disclosed. Also described herein are immune cells, viral vectors, and other compositions containing the antibodies, the antigen binding fragments, the chimeric antigen receptors, and / or the chimeric antigen receptor transgenes.
Owner:SANA BIOTECHNOLOGY INC

Reduced immunogenic gene therapy protocols using circular, extended cruciform containing non-viral vectors

Provided herein are non-immunogenic, circular, non-integrating, non-viral DNA vectors, and methods of using such DNA vectors, which are capable of forming one or more specialized secondary structures, for example extended cruciform structures, and express one or more therapeutic genes. These DNA vectors capable of forming one or more specialized secondary structures, for example extended cruciform structures, provide for increased nucleus entry, episomal stability, and long-term transgene expression, and have unique and highly unexpectedly reduced immunogenicity. The one or more specialized secondary structures, for example extended cruciform structures, formed by the circular DNA vectors provided herein are stabilized through the interaction of two specifically oriented repeating sequences, for example AAV-derived inverted terminal repeat (ITR) sequences, separated by a small, non-repeating sequence, for example a non-repeating sequence comprising a small bacterial origin of replication (Ori).
Owner:RAMPART BIOSCIENCE INC

Recombinant adeno-associated virus vector for retinal gene delivery and application thereof

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.
Owner:SHANGHAI LANGSHENG BIOTECHNOLOGY CO LTD

Oncolytic viral vectors and uses thereof

Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
Owner:VIROGIN BIOTECH CANADA LTD

Adeno-associated virus as well as preparation method and application thereof

The invention relates to the field of biological medicine, in particular to an adeno-associated virus as well as a preparation method and application thereof. The capsid protein of the adeno-associated virus AAV-ACM205 provided by the invention comprises a wild type AAV2 capsid protein or a variant of the wild type AAV2 capsid protein, the wild type AAV2 capsid protein or the variant of the wild type AAV2 capsid protein comprises peptide fragments with amino acid sequences as shown in SEQ ID NO.6 and SEQ ID NO.7, and a random peptide fragment is inserted between the SEQ ID NO.6 and the SEQ ID NO.7. The adeno-associated virus vector AAV-ACM205 provided by the invention can mediate a target gene to be specifically and efficiently expressed in hair cells in cochlea of an adult mouse under the condition of semicircular canal injection; the adeno-associated virus vector AAV-ACM205 mediated target gene expression is more flexible and efficient than that of a traditional transgenic method, is convenient to apply and low in cost, and has a wide prospect in ear disease gene therapy.
Owner:SHANGHAI EMAYGENE TECH CO LTD +1

Continuous directed evolution

The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved. Some aspects of this invention provide evolved products obtained from continuous evolution procedures described herein. Kits containing materials for continuous evolution are also provided.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Skeletal muscle targeting AAV capsid protein variants and uses thereof

The present invention relates to an adeno-associated virus (AAV) capsid protein variant having an amino acid mutation at the 328th to 331st amino acid residues of the AAV capsid protein relative to the 328th to 331st amino acid residues of the parent AAV capsid protein, for example, an amino acid sequence as shown in SEQ ID NO: 4 to replace the 328th to 331st amino acid residues of the parent AAV capsid protein wherein the amino acid position is numbered according to SEQ ID NO: 5. The invention also relates to an isolated nucleic acid encoding the AAV capsid protein variant, a nucleic acid vector comprising the same, and a host cell. The present invention also relates to a recombinant adeno-associated virus (rAAV) vector comprising said capsid protein variant, a pharmaceutical composition comprising said rAAV vector, and uses thereof in the treatment or prevention of skeletal muscle diseases.
Owner:BEIJING GENECRADLE PHARM CO LTD

Screening method for signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells - Patents.com

The present disclosure is directed to a method for screening signal peptides for efficient expression and secretion of heterologous polypeptides in mammalian cells, comprising: providing a pool of viral expression vectors encoding a polypeptide of interest comprising a variety of candidate signal peptides, wherein each viral expression vector of the pool comprises at least a polynucleotide encoding a fusion protein, the polynucleotide comprising: (i) a promoter, (ii) a sequence encoding a signal peptide, (iii) a sequence encoding a polypeptide of interest, (iv) optionally, a sequence encoding an epitope tag, and (v) a sequence encoding a C-terminal signal peptide for glycosylphosphatidylinositol (GPI) attachment or a sequence encoding a transmembrane domain; hosting the viral vector pool such that each host cell is preferably transformed with only one viral vector from the pool on average. The method includes the steps of transforming a host cell; expressing the fusion protein in the host cell to produce a fusion protein that is anchored to the host cell surface by a GPI or a transmembrane domain of the fusion protein; contacting the host cell with a first binding reagent, preferably an antibody that specifically binds to the target polypeptide; or, if an epitope tag is present in the fusion protein, a first binding reagent that specifically binds to the epitope tag; contacting the host cell with the first binding reagent, which may optionally be labeled with a fluorescent label or other detection means; dividing the transformed host cells into at least two groups based on the fluorescent properties of each host cell; and performing next-generation sequencing on the group of host cells that show the most efficient fusion protein expression to identify the optimal signal peptide for the target polypeptide in the host cell. The present disclosure is also directed to the vector, host cell, or DNA library used in the method.
Owner:ヘルシンギン イリオピスト

Human metapneumovirus viral vector-based vaccines

The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.
Owner:SANOFI PASTEUR INC

Methods of producing microbubble drug conjugates, viral gene therapy microbubble conjugates and targeted microbubbles

The present invention relates to methods of producing microbubble drug conjugates, viral gene therapy microbubble drug conjugates, and disease-targeting microbubbles, for clinical and preclinical ultrasound-mediated therapeutic and diagnostic applications. It includes methods to produce viral vector gene therapy microbubble drug conjugates with antibody linkers conjugated to lipid shelled microbubbles that both bind to and neutralize viral vectors such that the viral gene therapy can transduce and effect permanent genetic changes only after ultrasound is used to disassociate the viral gene therapy from microbubbles at diseased regions of the body.
Owner:KEENAN JAMES ALEXANDER

Reversing aging of the central nervous system

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Membrane protein replacement type oncolytic virus vector and application thereof

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.
Owner:SHANGHAI JIAOTONG UNIV